Does Rallies show 13F holders for SRRK?

Yes. Rallies tracks hedge fund and 13F ownership data for SRRK, including fund names, share counts, latest tracked quarter, and position changes when available.

Is SRRK research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SRRK. It does not provide personalized investment advice.

SRRK (Scholar Rock Holding Corporation Common Stock) Stock Analysis - Hedge Fund Holdings

Scholar Rock Holding Corporation Common Stock (SRRK) is a publicly traded Healthcare sector company. As of May 20, 2026, SRRK trades at $48.35 with a market cap of $5.68B and a P/E ratio of -14.80. SRRK moved +1.68% today. Year to date, SRRK is +13.14%; over the trailing twelve months it is +53.39%. Its 52-week range spans $6.76 to $51.63. Analyst consensus is strong buy with an average price target of $60.17. Rallies surfaces SRRK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns SRRK stock?

Hedge funds tracked by Rallies that own SRRK include Redmile Group, Orbimed Advisors, Polen Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Scholar Rock Holding Corporation Common Stock.

SRRK Key Metrics

Key financial metrics for SRRK
Metric	Value
Price	$48.35
Market Cap	$5.68B
P/E Ratio	-14.80
EPS	$-3.29
Dividend Yield	0.00%
52-Week High	$51.63
52-Week Low	$6.76
Volume	765.77K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-377.94M
Gross Margin	0.00%

Top Hedge Funds Holding SRRK

Redmile Group holds 9.07M shares of SRRK, changed +73.66% as of Mar 31, 2026.
Orbimed Advisors holds 151.80K shares of SRRK, changed +0.00% as of Mar 31, 2025.
Polen Capital holds 51.95K shares of SRRK, changed +138.72% as of Mar 31, 2026.
Farallon Capital holds 7.00K shares of SRRK, changed +0.00% as of Mar 31, 2026.

Latest SRRK News

Scholar Rock slides as Q1 results highlight apitegromab BLA acceptance and site reinspection — May 7, 2026
Scholar Rock rises as apitegromab FDA resubmission refocuses bulls on September 2026 decision — Apr 28, 2026
Scholar Rock slides as post-SRC compliance costs and dilution fears weigh on shares — Apr 22, 2026
Scholar Rock drops as investors price dilution risk after recent FDA BLA resubmission rally — Apr 20, 2026
Scholar Rock slides as apitegromab approval timing uncertainty returns to focus — Mar 28, 2026

Recent SRRK Insider Trades

Woods Keith sold 10.22K (~$506.65K) on Apr 16, 2026.
Vaishnaw Akshay sold 12.25K (~$607.09K) on Apr 16, 2026.
Sinha Vikas sold 10.41K (~$516.07K) on Apr 16, 2026.

SRRK Analyst Consensus

15 analysts cover SRRK: 0 strong buy, 15 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $60.17.

Common questions about SRRK

Who owns SRRK stock?: Hedge funds tracked by Rallies that own SRRK include Redmile Group, Orbimed Advisors, Polen Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Scholar Rock Holding Corporation Common Stock.
Does Rallies show 13F holders for SRRK?: Yes. Rallies tracks hedge fund and 13F ownership data for SRRK, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SRRK research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SRRK. It does not provide personalized investment advice.